The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma.
Jong Hyun ChoiJuwhan ChoiSang Mi ChungJee Youn OhYoung Seok LeeKyung Hoon MinGyu Young HurJae Jeong ShimKyung Ho KangHyun Kyung LeeSung-Yong LeePublished in: Tuberculosis and respiratory diseases (2018)
Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.